FY2025 saw a 2.9% drop in net sales and a 71.6% decline in operating profit, driven by lower overseas revenue and higher R&D costs. FY2026 guidance anticipates further declines due to generic competition and NHI price revisions, despite growth in select new drugs.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.